Home › Idiopathic Thrombocytopenic Purpura › New York
Idiopathic Thrombocytopenic Purpura clinical trials in New York
7 studies for Idiopathic Thrombocytopenic Purpura are looking for participants at sites in New York.
Cities in New York
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
- Montefiore Medical Center, The Bronx
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07421167A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Montefiore Medical Center, The Bronx
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07104565A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- NY Cancer and Blood Specialists, Shirley
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 11, 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
- New York Oncology Hematology-Investigational Site Number: 8400010, Albany
- Montefiore Medical Center-Investigational Site Number: 8400012, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 22, 2026 · NCT07007962Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
- New York Medical College, Vahalla
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Apr 15, 2026 · NCT04323748From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.